GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » Earnings per Share (Diluted)

PetVivo Holdings (PetVivo Holdings) Earnings per Share (Diluted) : $-0.86 (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings Earnings per Share (Diluted)?

PetVivo Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.12. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.86.

PetVivo Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.86.

PetVivo Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.81.

During the past 3 years, the average EPS without NRIGrowth Rate was -30.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.80% per year.

During the past 13 years, PetVivo Holdings's highest 3-Year average EPS without NRI Growth Rate was 63.20% per year. The lowest was -30.30% per year. And the median was 17.35% per year.


PetVivo Holdings Earnings per Share (Diluted) Historical Data

The historical data trend for PetVivo Holdings's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings Earnings per Share (Diluted) Chart

PetVivo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 -0.39 -0.57 -0.57 -0.85

PetVivo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.21 -0.25 -0.28 -0.12

Competitive Comparison of PetVivo Holdings's Earnings per Share (Diluted)

For the Medical Devices subindustry, PetVivo Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetVivo Holdings's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where PetVivo Holdings's PE Ratio falls into.



PetVivo Holdings Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

PetVivo Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.718-0)/10.223
=-0.85

PetVivo Holdings's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.75-0)/14.272
=-0.12

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


PetVivo Holdings  (OTCPK:PETV) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PetVivo Holdings Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


PetVivo Holdings (PetVivo Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5251 Edina Industrial Boulevard, Edina, MN, USA, 55439
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.
Executives
James Rudolph Martin director POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc 10 percent owner 43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt director 3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper director 201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai director, 10 percent owner, officer: CEO 12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius director 6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge director 345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes officer: Chief Financial Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson director 475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin director 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash director
John Michael Carruth officer: Acting Chief Financial Officer 4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood director 377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming director 16200 45TH STREET SOUTH, AFTON MN 55001